November 28, 2017 5:51pm

Risk, sentiment, a clinical data void and the dependence on capital market access hinders upside as investors scratch their heads about who’s next to finance i.e. depreciate and dilute or have trouble populating their trials

 

How right does one have to be? You could and should be reading this review of the day’s share pricing activity?

Is the truth so hard to fathom – that’s why my readership has grown exponentially!

 


Members only. Please login.